Positive Final Results Returned from Phase 2 Clinical Trials using Satipharm Capsules

TSXV – HVT

VANCOUVER, July 24, 2018 /CNW/ – Harvest One Cannabis Inc. (TSXV: HVT) (“Harvest One” or the “Company“), through its wholly-owned subsidiary Satipharm AG (“Satipharm“), is pleased to advise that positive results have been returned from the completed Phase 2 clinical trials undertaken by Israeli-based PhytoTech Therapeutics (“PTL“) that used Satipharm’s proprietary CBD capsules. The completed Phase 2 trial is an open-label, single-centre clinical study to evaluate the safety, tolerability and efficacy of oral administration of Satipharm CBD capsules as an adjunctive treatment. As previously announced, Harvest One is to acquire PTL from MMJ PhytoTech Limited (“MMJ“), pending MMJ shareholder and TSXV approval.

“This is a step forward for Harvest One’s pharma and nutraceutical strategy,” said Grant Froese, CEO of Harvest One. “Continuing to develop products that will aid individuals and enrich their lives will continue to be a core component of our medical strategy moving

... read more at: https://www.newswire.ca/news-releases/positive-final-results-returned-from-phase-2-clinical-trials-using-satipharm-capsules-688986551.html

by

Leave a Reply